uniQure N.V. filings document regulatory, financial, governance, and capital-structure disclosures for a Nasdaq-listed gene therapy company incorporated in the Netherlands. Form 8-K reports cover operating results, corporate updates, Regulation FD disclosures, and clinical or regulatory communications involving programs such as AMT-130 for Huntington’s disease.
Proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and related pay-versus-performance disclosures. The filing record also includes formal disclosure categories for material agreements, financing arrangements, risk-related updates, and capital-structure matters connected to uniQure’s development-stage gene therapy portfolio.
uniQure N.V. (QURE) announced an at-the-market (ATM) equity offering program via Form 8-K. Under a new Sales Agreement dated 29 Jul 2025, Leerink Partners LLC will act as sales agent to place up to $200 million of ordinary shares (€0.05 par value) from time to time. Sales may occur on Nasdaq, other U.S. trading venues or through negotiated transactions, and will be executed on a “commercially reasonable efforts” basis.
Key terms:
- Commission: up to 3.0% of gross proceeds to Leerink Partners.
- No obligation: uniQure can choose whether, when and how much stock to sell; the agreement terminates after all shares are sold or upon earlier termination by the parties.
- Registration: shares will be issued under the company’s effective shelf registration statement (Form S-3ASR, File No. 333-284168).
- Legal opinions & exhibits: Sales Agreement (Ex. 1.1), legal opinion (Ex. 5.1) and related consents filed.
The facility enhances capital-raising flexibility but may dilute existing shareholders if fully utilized. No immediate share issuance or financial impact is disclosed.
uniQure N.V. (QURE) filed a prospectus supplement for an “at-the-market” equity program of up to $200 million in ordinary shares, par €0.05, to be sold from time to time through Leerink Partners LLC.
Leerink will act as sales agent and is entitled to a commission of up to 3 % of gross proceeds and will be treated as an underwriter. Shares will be issued on The Nasdaq Global Select Market at prevailing prices. Using the 25-Jul-2025 close of $15.11, a full draw would add roughly 13.24 m shares, lifting total shares outstanding to 68.10 m.
- Post-offering pro-forma net tangible book value rises from −$2.08 to $1.17 per share, creating immediate dilution of $13.94 for new investors.
- Proceeds will fund the potential U.S. launch of lead gene-therapy AMT-130, advance multiple clinical programs (AMT-260, AMT-191, AMT-162), support business development and general corporate needs.
- Risk highlights: discretionary use of funds, potential share-price pressure from sales, extensive outstanding equity awards, PFIC classification for 2024, no dividend policy and share-price volatility.
There is no minimum sale requirement and proceeds are not escrowed, giving the company flexibility but leaving investors uncertain about timing and pricing of dilution.
Director Jeremy P. Springhorn of uniQure reported a sale of 2,112 ordinary shares on June 20, 2025, at a weighted average price of $14.45 per share (range: $14.40-$14.50). Following the transaction, Springhorn retains direct ownership of 37,694 shares.
Key details of the transaction:
- The sale was non-discretionary, executed automatically to cover estimated tax withholding obligations upon the vesting of restricted share units
- Transaction was conducted under automatic sale instructions included in the Restricted Share Unit Agreement
- The Form 4 was filed by Christian Klemt as attorney-in-fact
This transaction appears to be a routine share sale for tax purposes rather than a strategic investment decision by the director.
uniQure Director Leonard E. Post reported a non-discretionary sale of 2,112 ordinary shares on June 20, 2025 at a weighted average price of $14.45 per share (range: $14.40-$14.50). The transaction was executed to cover estimated withholding taxes following the vesting of restricted share units, according to automatic sale instructions in the Restricted Share Unit Agreement.
Following the reported transaction, Post continues to directly own 29,937 ordinary shares of uniQure. The sale was conducted through automatic sale instructions and was not a discretionary trade by the reporting person.
- Transaction Type: Non-discretionary sale (tax withholding)
- Total Transaction Value: Approximately $30,518
- Ownership Form: Direct
- Filing was signed by Christian Klemt as Attorney-in-Fact
Director Jack Kaye of uniQure reported a non-discretionary sale of 2,112 ordinary shares on June 20, 2025 at a weighted average price of $14.45 per share (range: $14.40-$14.50). Following the transaction, Kaye retains direct ownership of 20,439 shares.
Key transaction details:
- The sale was automatically executed to cover estimated tax withholding obligations upon the vesting of restricted share units
- Transaction was made pursuant to automatic sale instructions in the Restricted Share Unit Agreement
- The sale was non-discretionary and not a voluntary trade by the director
- Form was filed through an attorney-in-fact on June 24, 2025
uniQure director Rachelle Suzanne Jacques reported a non-discretionary sale of 2,112 ordinary shares on June 20, 2025 at a weighted average price of $14.45 per share (range: $14.40-$14.50).
Key details of the transaction:
- The sale was automatically executed to cover estimated withholding taxes upon vesting of restricted share units
- Transaction was made according to automatic sale instructions in the Restricted Share Unit Agreement
- Following the transaction, Jacques continues to hold 28,346 ordinary shares directly
- The filing was signed by Christian Klemt as attorney-in-fact on June 24, 2025
This transaction represents a routine tax-related share sale rather than a discretionary trading decision by the insider.